摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

BENZOICACID,4-鈥媅3-鈥媅(4-鈥媘ETHYLPHENYL)鈥媡HIO]鈥鈥-鈥媅[(4-鈥媘ETHYLPHENYL)鈥媡HIO]鈥媘ETHYL]鈥鈥-鈥媜XOPROPYL]鈥 | 124242-93-9

中文名称
BENZOICACID,4-鈥媅3-鈥媅(4-鈥媘ETHYLPHENYL)鈥媡HIO]鈥鈥-鈥媅[(4-鈥媘ETHYLPHENYL)鈥媡HIO]鈥媘ETHYL]鈥鈥-鈥媜XOPROPYL]鈥
中文别名
——
英文名称
4-(3-(p-tolylthio)-2-((p-tolylthio)methyl)propanoyl)benzoic acid
英文别名
4-[3-(4-methylphenyl)sulfanyl-2-[(4-methylphenyl)sulfanylmethyl]propanoyl]benzoic acid
BENZOICACID,4-鈥媅3-鈥媅(4-鈥媘ETHYLPHENYL)鈥媡HIO]鈥鈥-鈥媅[(4-鈥媘ETHYLPHENYL)鈥媡HIO]鈥媘ETHYL]鈥鈥-鈥媜XOPROPYL]鈥化学式
CAS
124242-93-9
化学式
C25H24O3S2
mdl
——
分子量
436.596
InChiKey
VIRBIYLSQCHFHW-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    6.2
  • 重原子数:
    30
  • 可旋转键数:
    9
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.2
  • 拓扑面积:
    105
  • 氢给体数:
    1
  • 氢受体数:
    5

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • A Disulfide Intercalator Toolbox for the Site-Directed Modification of Polypeptides
    作者:Tao Wang、Yuzhou Wu、Seah Ling Kuan、Oliver Dumele、Markus Lamla、David Y. W. Ng、Matthias Arzt、Jessica Thomas、Jan O. Mueller、Christopher Barner-Kowollik、Tanja Weil
    DOI:10.1002/chem.201403965
    日期:2015.1.2
    A disulfide intercalator toolbox was developed for site‐specific attachment of a broad variety of functional groups to proteins or peptides under mild, physiological conditions. The peptide hormone somatostatin (SST) served as model compound for intercalation into the available disulfide functionalization schemes starting from the intercalator or the reactive SST precursor before or after bioconjugation
    开发了一种二硫键嵌入剂工具箱,用于在温和的生理条件下将各种官能团定点连接到蛋白质或肽上。肽激素生长抑素(SST)用作模型化合物,可在生物缀合之前或之后从嵌入剂或反应性SST前体插入到可用的二硫键官能化方案中。获得了四唑-SST衍生物,该衍生物在哺乳动物细胞中经历了光诱导的环加成反应,并通过活细胞成像进行了监测。
  • Derivatisation of biological molecules
    申请人:BIOCOMPATIBLES UK LIMITED
    公开号:US09109016B2
    公开(公告)日:2015-08-18
    The present disclosure relates to a new polymerisation process in which ethylenically unsaturated monomers are polymerised by a living radical polymerisation process in the presence of an initiator and a catalyst. Polymers produced by this new process are also thought to be novel and may be used to derivatise biological molecules to improve their efficacy as therapeutic treatments. A preferred polymer is of formula The polymers are particularly suitable for derivatising proteins, such as interferon-α.
    本公开涉及一种新的聚合过程,其中乙烯不饱和单体通过活性自由基聚合过程在引发剂和催化剂的存在下聚合。由这种新过程产生的聚合物也被认为是新颖的,并可用于衍生生物分子,以提高其作为治疗药物的功效。一种优选的聚合物为公式所示。这些聚合物特别适用于衍生蛋白质,如干扰素-α。
  • Receptor selective ruthenium-somatostatin photosensitizer for cancer targeted photodynamic applications
    作者:Tao Wang、Natalia Zabarska、Yuzhou Wu、Markus Lamla、Stephan Fischer、Katharina Monczak、David Y. W. Ng、Sven Rau、Tanja Weil
    DOI:10.1039/c5cc03473f
    日期:——

    The efficient conjugation of a ruthenium complex and the peptide hormone somatostatin is presented. The resultant biohybrid offers many valuable features for photodynamic therapy.

    提出了一种有效的钌配合物与肽激素生长抑素的结合。所得的生物杂交体为光动力疗法提供了许多有价值的特性。
  • Dimerization of the Peptide CXCR4-Antagonist on Macromolecular and Supramolecular Protraction Arms Affords Increased Potency and Enhanced Plasma Stability
    作者:Mirja Harms、Rikke Fabech Hansson、Sheiliza Carmali、Yasser Almeida-Hernández、Elsa Sanchez-Garcia、Jan Münch、Alexander N. Zelikin
    DOI:10.1021/acs.bioconjchem.2c00034
    日期:2022.4.20
    Peptides are prime drug candidates due to their high specificity of action but are disadvantaged by low proteolytic stability. Here, we focus on the development of stabilized analogues of EPI-X4, an endogenous peptide antagonist of CXCR4. We synthesized macromolecular peptide conjugates and performed side-by-side comparison with their albumin-binding counterparts and considered monovalent conjugates, divalent telechelic conjugates, and Y-shaped peptide dimers. All constructs were tested for competition with the CXCR4 antibody–receptor engagement, inhibition of receptor activation, and inhibition of the CXCR4-tropic human immunodeficiency virus infection. We found that the Y-shaped conjugates were more potent than the parent peptide and at the same time more stable in human plasma, with a favorable outlook for translational studies.
    多肽具有高度特异性,是候选药物的首选,但其缺点是蛋白水解稳定性低。在此,我们将重点放在开发 EPI-X4 的稳定类似物上,EPI-X4 是一种 CXCR4 的内源性多肽拮抗剂。我们合成了大分子肽共轭物,并将其与白蛋白结合的对应物进行了并排比较,还考虑了单价共轭物、二价远缘共轭物和 Y 型肽二聚体。我们测试了所有构建物与 CXCR4 抗体-受体啮合的竞争性、对受体活化的抑制性以及对 CXCR4 热带人类免疫缺陷病毒感染的抑制性。我们发现 Y 型共轭物比母肽更有效,同时在人体血浆中也更稳定,这为转化研究带来了良好的前景。
  • Conjugation reagents
    申请人:POLYTHERICS LIMITED
    公开号:US10174125B2
    公开(公告)日:2019-01-08
    The invention provides compound of the general formula: in which each X independently represents a polymer chain; n represents an integer greater than 1; Q represents a linker; Y represents an amide group; and Z represents either —CH.(CH2L)2 or —C(CH2L)(═CH2), in which each L independently represents a leaving group. The compounds are useful reagents for the conjugation of polymers to proteins, the resulting conjugates being novel and also forming part of the invention.
    本发明提供了通式为 其中每个 X 独立地代表聚合物链;n 代表大于 1 的整数;Q 代表连接剂;Y 代表酰胺基;Z 代表-CH.(CH2L)2 或-C(CH2L)(═CH2),其中每个 L 独立地代表离去基团。这些化合物是将聚合物与蛋白质共轭的有用试剂,所得到的共轭物是新颖的,也是本发明的一部分。
查看更多